{
  "image_filename": "table_p13_det_12_007.png",
  "image_path": "Grohskopf_et_al.__2023_/extracted/figures/table_p13_det_12_007.png",
  "image_type": "Table",
  "page_number": 13,
  "block_id": "det_12_007",
  "claim_id": "claim_002",
  "claim": "Cell- and egg-based flu vaccines have the potential to develop mutations during production, which may reduce their effectiveness.",
  "supports_claim": false,
  "explanation": "Table listing trade names and manufacturers of quadrivalent influenza vaccines and the dose volumes (\u00b5g HA per vaccine virus) for children aged 6 through 35 months. does not support the claim because the table only provides vaccine names, manufacturers, and pediatric dosing volumes, with no information on production methods, mutations, or effectiveness.",
  "model_used": "o4-mini",
  "detailed_analysis": {
    "supports_claim": false,
    "image_description": "Table listing trade names and manufacturers of quadrivalent influenza vaccines and the dose volumes (\u00b5g HA per vaccine virus) for children aged 6 through 35 months.",
    "evidence_found": null,
    "reasoning": "does not support the claim because the table only provides vaccine names, manufacturers, and pediatric dosing volumes, with no information on production methods, mutations, or effectiveness.",
    "confidence_notes": null
  }
}